Kymera Therapeutics Inc
Open
SectorGezondheidszorg
87 1.03
Overzicht
Wijziging aandelenprijs
24u
Min
83.94
Max
87.81
Inkomsten | 18M -69M |
|---|---|
Verkoop | 32M 34M |
EPS | -0.71 |
Winstmarge | -201.467 |
Werknemers | 253 |
EBITDA | 18M -67M |
Aanbevelingen | Strong Buy |
|---|---|
12 Maanden Prognose | +37.02% upside |
Volgende Winsten | 11 aug 2026 |
|---|
Marktkapitalisatie | -979M 6.1B |
|---|---|
Vorige openingsprijs | 85.97 |
Vorige sluitingsprijs | 87 |
Nieuwssentiment
By Acuity
50%
50%
146 / 342 Rangschikking in Healthcare
Kymera Therapeutics Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Over Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.